Business Context and Reporting Period
Company: Compass Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 4, 2022
Reporting Period: Event-driven report regarding clinical trial data announced on May 4, 2022.
Key Financial Metrics
This filing is a current report regarding clinical trial updates and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the announcement of positive interim data from an ongoing Phase 2 clinical trial for the Company's clinical program, CTX-009. The trial assesses CTX-009 in combination with paclitaxel for the treatment of advanced biliary tract cancers.
Guidance, Outlook, and Management Commentary
- Clinical Update: Management announced positive interim Phase 2 data for CTX-009 in combination with paclitaxel in advanced biliary tract cancers.
- Investor Communication: The Company hosted a conference call on May 4, 2022, to discuss the interim data. A slide presentation was provided as Exhibit 99.2.
- Legal Disclaimer: The information in Item 7.01, including the press release and presentation, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference.
Important Facts for Investor Verification
- Verify the specific statistical outcomes and safety profile details of the CTX-009 Phase 2 interim data in the attached press release (Exhibit 99.1).
- Review the slide presentation (Exhibit 99.2) for management's interpretation of the data and potential next steps for the clinical program.
- Confirm that the clinical data is not considered "filed" information under Section 18 of the Exchange Act, limiting liability protections for the disclosed data.
- Check subsequent filings (e.g., 10-Q or 10-K) for the financial impact of ongoing clinical trials, as this 8-K contains no financial metrics.